Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,108
archived clinical trials in
Lupus

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Middleburg Heights, OH
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tulsa, OK
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Duncansville, PA
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charleston, SC
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Myrtle Beach, SC
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jackson, TN
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jackson, TN
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Amarillo, TX
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Amarillo, TX
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mesquite, TX
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mesquite, TX
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
mi
from
Camperdown,
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
mi
from
Camperdown,
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Clair Shores, MI
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Clair Shores, MI
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
On Open-Label Study in Participants With Systemic Lupus Erythematosus
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Irving, TX
On Open-Label Study in Participants With Systemic Lupus Erythematosus
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Irving, TX
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
La Palma, CA
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
La Palma, CA
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Long Beach, CA
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Palm Desert, CA
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Palm Desert, CA
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Upland, CA
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Upland, CA
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ocala, FL
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orlando, FL
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Stockbridge, GA
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Stockbridge, GA
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Las Cruces, NM
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Las Cruces, NM
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tulsa, OK
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Spokane, WA
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
mi
from
Rio de Janeiro,
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
mi
from
Rio de Janeiro,
Click here to add this to my saved trials
Monoclonal Antibody Treatment for Systemic Lupus Erythematosus
A Phase I, Open-Labeled, Dose-Ascending Clinical Trial of Immunotherapy of MRA, A Humanized Anti-IL 6 Receptor Monoclonal Antibody, In Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Monoclonal Antibody Treatment for Systemic Lupus Erythematosus
A Phase I, Open-Labeled, Dose-Ascending Clinical Trial of Immunotherapy of MRA, A Humanized Anti-IL 6 Receptor Monoclonal Antibody, In Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
University of Arizona
mi
from
Tucson, AZ
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Medvin Clinical Research
mi
from
Covina, CA
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Medvin Clinical Research
mi
from
Covina, CA
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
TriWest Research Assocaites
mi
from
El Cajon, CA
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
TriWest Research Assocaites
mi
from
El Cajon, CA
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Desert Medical Advances
mi
from
Palm Desert, CA
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Desert Medical Advances
mi
from
Palm Desert, CA
Click here to add this to my saved trials